{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Participants who receive standard of care plus treatment with ex vivo cultured adult human mesenchymal stem cells.",
            "Participants who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells."
      ],
      "ArmGroupInterventionName": [
            "Biological: Prochymal\u00ae",
            "Drug: Standard of Care for GVHD",
            "Drug: Placebo",
            "Drug: Standard of Care for GVHD"
      ],
      "ArmGroupLabel": [
            "Prochymal\u00ae",
            "Placebo"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT00366145"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal\u00ae in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD."
      ],
      "BriefTitle": [
            "Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "May 28, 2009"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Graft Versus Host Disease"
      ],
      "ConditionAncestorId": [
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC20",
            "All",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Immune System Diseases",
            "All Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Graft Versus Host Disease",
            "Graft Versus Host Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafId": [
            "M8341",
            "M9352",
            "T2832",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "Graft vs Host Disease",
            "Immune System Diseases",
            "Homologous Wasting Disease",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000006086"
      ],
      "ConditionMeshTerm": [
            "Graft vs Host Disease"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Approximately 6300 patients receive allogeneic hematopoietic stem cell transplants in the United States each year (International Bone Marrow Transplant Registry [IBMTR], 2003). Nearly 50% (approximately 3,150) of these patients develop acute GVHD (Goker et al). A fraction of these patients (approximately 870) will progress to the severe stages of the disease, Grades III-IV. It is estimated that nearly 82% of those patients with severe acute GVHD will be steroid refractory (Przepiorka et al., 1995) and of these, only 50% of steroid-refractory patients will respond to secondary and tertiary treatments (Greinix et al., 2000). Thus, roughly 350 patients each year face tremendous odds against survival. In addition, most patients who initially responded to secondary and tertiary treatments have a high risk of dying within the first year (Remberger et al., 2001; Anasetti et al., 1994). Development of new therapeutic agents and strategies to rescue patients with steroid refractory, acute GVHD would provide a significant benefit in an area of unmet medical need. Participants will receive standard of care in addition to adult mesenchymal stem cells or placebo."
      ],
      "DispFirstPostDate": [
            "April 25, 2011"
      ],
      "DispFirstPostDateType": [
            "Estimate"
      ],
      "DispFirstSubmitDate": [
            "August 24, 2010"
      ],
      "DispFirstSubmitQCDate": [
            "April 8, 2011"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nParticipant must be 6 months to 70 years of age, inclusive.\nParticipants who have failed to respond to steroid treatment.\n\nFailure to respond to steroid treatment is defined as any grade B-D (IBMTR) grading of acute GVHD that shows:\n\nNo improvement after 3 days and a duration of no greater than 2 weeks while receiving treatment with methylprednisolone (greater than or equal to 1 mg/kg/day) or equivalent.\nParticipant must be treated within 4 days of randomization. In urgent situations 2nd line therapy may be started 24 hours prior to randomization, and Prochymal\u00ae must be initiated within the following 3 days.\nParticipants who have received an increase in their steroid dose treatment prior to randomization will be eligible for enrollment. An increase in steroid dose will not be considered as second line therapy.\nParticipant must have adequate renal function as defined by: Calculated Creatinine Clearance of >30 milliliters per minute (mL/min) using the Cockcroft-Gault equation.\nFor pediatric participants: Schwartz equation: (Participant population: infants over 1 week old through adolescence (<18 years old).\nParticipants who are women of childbearing potential must be non-pregnant, not breast-feeding, and use adequate contraception. Male participants must use adequate contraception.\nParticipant must have a minimum Karnofsky Performance Level of at least 30 at the time of study entry.\nParticipant (or legal representative where appropriate) must be capable of providing written informed consent.\n\nExclusion Criteria:\n\nParticipant has started treatment with second line therapy >24 hours prior to randomization.\nParticipant has received agents other than steroids for primary treatment of acute GVHD.\nParticipant is participating in the CTN Protocol 0302.\nParticipant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant including uncontrolled infection, heart failure, pulmonary hypertension, etc.\nParticipant may not receive any other investigational agents (not approved by the FDA) concurrently during study participation or within 30 days of randomization.\nParticipant has a known allergy to bovine or porcine products.\nParticipant has received a transplant for a solid tumor disease."
      ],
      "EnrollmentCount": [
            "260"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [
            "D000000893",
            "D000000998",
            "D000000890"
      ],
      "InterventionAncestorTerm": [
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionArmGroupLabel": [
            "Prochymal\u00ae",
            "Placebo",
            "Placebo",
            "Prochymal\u00ae"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Infe",
            "Infl",
            "All"
      ],
      "InterventionBrowseBranchName": [
            "Anti-Infective Agents",
            "Anti-Inflammatory Agents",
            "All Drugs and Chemicals"
      ],
      "InterventionBrowseLeafAsFound": [
            "Unsuccessful"
      ],
      "InterventionBrowseLeafId": [
            "M186752",
            "M3369",
            "M3466",
            "M3366"
      ],
      "InterventionBrowseLeafName": [
            "Remestemcel-l",
            "Anti-Inflammatory Agents",
            "Antiviral Agents",
            "Anti-Infective Agents"
      ],
      "InterventionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "2 infusions of 2 million cells/kg per week for 4 weeks",
            "2 infusions per week for 4 weeks",
            "Institutionally defined standard of care (e.g., maintenance of steroid treatment and the addition of a second-line therapy)"
      ],
      "InterventionMeshId": [
            "C000711674"
      ],
      "InterventionMeshTerm": [
            "Remestemcel-l"
      ],
      "InterventionName": [
            "Prochymal\u00ae",
            "Placebo",
            "Standard of Care for GVHD"
      ],
      "InterventionOtherName": [
            "Mesenchymal Stem Cells",
            "excipients without adult human mesenchymal stem cells"
      ],
      "InterventionType": [
            "Biological",
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Acute GVHD",
            "Steroid refractory GVHD",
            "Severe steroid refractory acute GVHD",
            "Steroid refractory",
            "Steroid Refractory Acute Graft Versus Host Disease"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "February 10, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "February 9, 2022"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Inc."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Birmingham",
            "Tucson",
            "Duarte",
            "San Francisco",
            "New Haven",
            "Miami",
            "Saint Petersburg",
            "Atlanta",
            "Atlanta",
            "Chicago",
            "Chicago",
            "Chicago",
            "Beech Grove",
            "Iowa City",
            "Kansas City",
            "Louisville",
            "Shreveport",
            "Baltimore",
            "Boston",
            "Boston",
            "Boston",
            "Detroit",
            "Rochester",
            "Jackson",
            "Omaha",
            "Hackensack",
            "Buffalo",
            "New York",
            "New York",
            "New York",
            "Rochester",
            "Valhalla",
            "Durham",
            "Winston-Salem",
            "Portland",
            "Hershey",
            "Pittsburgh",
            "Charleston",
            "Dallas",
            "Dallas",
            "Dallas",
            "Houston",
            "San Antonio",
            "Richmond",
            "Seattle",
            "Madison",
            "Milwaukee",
            "Herston",
            "Parkville",
            "Perth",
            "Calgary",
            "Vancouver",
            "Winnipeg",
            "Halifax",
            "Hamilton",
            "London",
            "Ottawa",
            "Toronto",
            "Toronto",
            "Montreal",
            "Quebec",
            "Quebec",
            "Pesaro",
            "Pavia",
            "Basel",
            "London",
            "Headington",
            "Bristol",
            "Glasgow",
            "Leeds"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "Australia",
            "Australia",
            "Australia",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Canada",
            "Italy",
            "Italy",
            "Switzerland",
            "United Kingdom",
            "United Kingdom",
            "United Kingdom",
            "United Kingdom",
            "United Kingdom"
      ],
      "LocationFacility": [
            "University of Alabama at Birmingham",
            "Arizona Cancer Center",
            "City of Hope",
            "Univeristy of California San Francisco",
            "Yale New Haven Hospital",
            "University of Miami",
            "All Children's Hospital",
            "Emory University",
            "Northside Hospital",
            "Northwestern Center for Clinical Research",
            "Rush University Medical Center",
            "University of Illinois - Chicago",
            "Indiana Blood and Bone Marrow Transplant Center",
            "Univeristy of Iowa Hospitals and Clinics",
            "University of Kansas Medical Center",
            "University of Louisville",
            "Louisiana State University",
            "University of Maryland/Greenbaum",
            "Tufts-New England Medical Center",
            "Beth Israel Deaconess Medical Center",
            "Dana-Farber Cancer Institute",
            "Karmanos/Wayne State University",
            "Mayo Clinic Rochester",
            "Univeristy of Mississippi Medical Center",
            "University of Nebraska",
            "Hackensack University Medical Center",
            "Roswell Park",
            "New York Presbyterian Hospital",
            "Mount Sinai Medical Center",
            "Columbia University/New York Presbyterian Hospital",
            "University of Rochester",
            "New York Medical College",
            "Duke University",
            "Wake Forest Univeristy School of Medicine",
            "Oregon Health and Science University",
            "Penn State Hershey Medical Center",
            "Western Pennsylvania Cancer Institute",
            "Medical University of South Carolina",
            "Texas Cancer Center at Medical City",
            "Baylor University",
            "Univeristy of Texas Southwestern Medical Center",
            "MD Anderson Cancer Center",
            "Texas Research Center",
            "Virginia Commonwealth/Massey Cancer Center",
            "Fred Hutchinson Cancer Research Center",
            "University of Wisconsin Madison",
            "Medical College of Wisconsin",
            "Royal Brisbane Hospital",
            "Royal Melbourne Hospital",
            "Royal Perth Hospital",
            "Co-Medica Research Network",
            "British Columbia's Children's Hospital",
            "Cancer Care Manitoba",
            "Queen Elizabeth II Health Sciences Centre",
            "Hamilton Health Sciences Centre",
            "London Health Sciences Centre- Westminster Campus",
            "Ottawa Hospital",
            "Toronto General Hospital",
            "Princess Margaret Hospital",
            "Maisonneuve-Rosemont Hospital",
            "Hopital Enfant-Jesus",
            "Hopital du Saint-Sacrement",
            "Universia degli Studi di Pesaro",
            "IRCCS Policlinico San Matteo",
            "Kantonsspital Basel",
            "Barts & London School of Medicine",
            "John Radcliffe Hospital",
            "Bristol Royal Hospital for Children",
            "Glasgow Royal Infirmary",
            "Leeds General Infirmary"
      ],
      "LocationState": [
            "Alabama",
            "Arizona",
            "California",
            "California",
            "Connecticut",
            "Florida",
            "Florida",
            "Georgia",
            "Georgia",
            "Illinois",
            "Illinois",
            "Illinois",
            "Indiana",
            "Iowa",
            "Kansas",
            "Kentucky",
            "Louisiana",
            "Maryland",
            "Massachusetts",
            "Massachusetts",
            "Massachusetts",
            "Michigan",
            "Minnesota",
            "Mississippi",
            "Nebraska",
            "New Jersey",
            "New York",
            "New York",
            "New York",
            "New York",
            "New York",
            "New York",
            "North Carolina",
            "North Carolina",
            "Oregon",
            "Pennsylvania",
            "Pennsylvania",
            "South Carolina",
            "Texas",
            "Texas",
            "Texas",
            "Texas",
            "Texas",
            "Virginia",
            "Washington",
            "Wisconsin",
            "Wisconsin",
            "Queensland",
            "Victoria",
            "Western Australia",
            "Alberta",
            "British Columbia",
            "Manitoba",
            "Nova Scotia",
            "Ontario",
            "Ontario",
            "Ontario",
            "Ontario",
            "Ontario",
            "Quebec",
            "PU",
            "England",
            "Oxford",
            "UK",
            "UK",
            "UK"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "35249",
            "85724",
            "91010",
            "94143",
            "06520",
            "33136",
            "33701",
            "30322",
            "30342",
            "60611",
            "60612",
            "60612",
            "46107",
            "52242",
            "66160",
            "40202",
            "71130",
            "21201",
            "02111",
            "02215",
            "02215",
            "48201",
            "55905",
            "39216",
            "68198",
            "07601",
            "14263",
            "10021",
            "10029",
            "10032",
            "14642",
            "10595",
            "27710",
            "27157",
            "97239",
            "17033",
            "15224",
            "29425",
            "75230",
            "75246",
            "75390",
            "77030",
            "78229",
            "23298",
            "98109-1024",
            "53792",
            "53226",
            "4029",
            "3050",
            "6100",
            "T1Y6J4",
            "V6H3V4",
            "R3E0V9",
            "B3H2Y9",
            "L8N3Z5",
            "N6A4G5",
            "K1H8L6",
            "M5G 1X8",
            "M5G1X8",
            "H1T 2M4",
            "G1J 1Z4",
            "G1S4L8",
            "61100",
            "27100",
            "4031",
            "EC1M 6BQ",
            "OX3 0Du",
            "BS2 8BJ",
            "G4 OSF",
            "LS1 3EX"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "6 Months"
      ],
      "NCTIdAlias": [
            "NCT00476840"
      ],
      "OfficialTitle": [
            "A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal\u00ae (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "280"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Inc."
      ],
      "OverallOfficialName": [
            "Christopher James, PA"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 26, 2008"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "A complete response was defined as complete resolution of all clinical signs of Graft versus host disease (GVHD)- that had to be maintained for at least 28 consecutive days (durable complete response [DCR]) within 100 days post first infusion."
      ],
      "PrimaryOutcomeMeasure": [
            "Percentage of Participants achieving Complete Response of Greater Than or Equal to 28 Days Duration"
      ],
      "PrimaryOutcomeTimeFrame": [
            "up to 100 Days post first infusion"
      ],
      "ReferenceCitation": [
            "Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8.",
            "Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. Review.",
            "Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98.",
            "Le Blanc K, Rasmusson I, Sundberg B, G\u00f6therstr\u00f6m C, Hassan M, Uzunel M, Ringd\u00e9n O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.",
            "Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. Review.",
            "Camilleri ET, Gustafson MP, Dudakovic A, Riester SM, Garces CG, Paradise CR, Takai H, Karperien M, Cool S, Sampen HJ, Larson AN, Qu W, Smith J, Dietz AB, van Wijnen AJ. Identification and validation of multiple cell surface markers of clinical-grade adipose-derived mesenchymal stromal cells as novel release criteria for good manufacturing practice-compliant production. Stem Cell Res Ther. 2016 Aug 11;7(1):107. doi: 10.1186/s13287-016-0370-8."
      ],
      "ReferencePMID": [
            "11823036",
            "10989188",
            "15846293",
            "15121408",
            "16040382",
            "27515308"
      ],
      "ReferenceType": [
            "background",
            "background",
            "background",
            "background",
            "background",
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Percentage of participants who survived at 180 days post first infusion."
      ],
      "SecondaryOutcomeMeasure": [
            "Overall Survival at 180 days Post First Infusion"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Day 180"
      ],
      "SeeAlsoLinkLabel": [
            "Description Click here for more information about this study: A Phase III Study to Evaluate the Efficacy and Safety of Prochymal\u00ae (Ex vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid-Refractory Acute GVHD"
      ],
      "SeeAlsoLinkURL": [
            "http://www.osiris.com"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 17, 2006"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "February 2022"
      ],
      "StdAge": [
            "Child",
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "August 21, 2006"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "August 17, 2006"
      ],
      "StudyFirstSubmitQCDate": [
            "August 18, 2006"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}